Loading clinical trials...
Loading clinical trials...
Prophylactic Role Of Tranexamic Acid To Reduce Blood Loss During Caesarean Delivery : A Prospective Study.
Postpartum hemorrhage continues to be the leading cause of maternal morbidity and mortality. Globally, it is responsible for 25% of all pregnancy-related deaths. PPH is unpredictable and may occur in the absence of risk factors. Tranexamic acid is an antifibrinolytic proven to reduce blood loss and transfusion requirements for various surgeries. This study aims to explore the effectiveness of tranexamic acid as an adjunct to other uterotonics before the Caesarian Section.
Age
18 - 45 years
Sex
FEMALE
Healthy Volunteers
No
ASJSATDS Medical College
Fatehpur, Uttar Pradesh, India
Start Date
October 1, 2024
Primary Completion Date
March 30, 2025
Completion Date
March 30, 2025
Last Updated
October 24, 2024
300
ESTIMATED participants
Tranexamic acid injection
DRUG
Placebo
DRUG
Lead Sponsor
Aligarh Muslim University
NCT05370820
NCT05977686
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06513351